Designing an In Vitro Permeation Test (IVPT) study for a topical drug product requires much more than selecting a diffusion cell and applying a formulation to skin. A scientifically useful IVPT study must control biological variability, experimental conditions, analytical measurement, and statistical design well enough to characterize how a drug permeates into and through the skin. This is especially important in topical pharmaceutical development because the skin is a complex biological barrier. IVPT performance can be influenced by:

• donor-to-donor variability;
• skin thickness and preparation;
• barrier integrity;
• dose application;
• receptor-medium composition;
• diffusion-cell conditions;
• sampling schedule;
• formulation properties;
• analytical sensitivity;
• and statistical design.

IVPT is widely used to study topical pharmacokinetics and formulation performance, and it can be particularly valuable in the development and comparison of locally acting topical products. For generic topical drug development, FDA’s current draft IVPT guidance describes the method as a potential component of a characterization-based approach to supporting bioequivalence when appropriately developed, validated, conducted, and analyzed. At topiox research, IVPT study design can therefore be approached as an integrated scientific problem involving skin biology, formulation science, diffusion testing, bioanalysis, statistics, and regulatory strategy.  

What Is IVPT Study Design?

IVPT study design is the structured selection of experimental, biological, analytical, and statistical conditions used to measure and compare the rate and extent of drug permeation from topical products through excised skin. A typical IVPT study may involve: Topical formulation ↓ Finite dose application ↓ Excised human skin ↓ Diffusion cell system ↓ Receptor medium ↓ Serial sampling ↓ Bioanalytical quantification ↓ Flux and cumulative permeation profiles ↓ Statistical comparison Unlike IVRT, which primarily evaluates release of the drug from the dosage form using a synthetic membrane system, IVPT uses a biological skin barrier and therefore captures the interaction between the formulation and skin. This makes IVPT particularly valuable for evaluating cutaneous drug delivery.  

Why IVPT Study Design Matters

IVPT is a sensitive experimental model, but that sensitivity also means poorly controlled study variables can introduce substantial noise. An IVPT study can fail to provide meaningful information if:

• skin sections vary excessively;
• donor numbers are insufficient;
• the skin barrier is compromised;
• receptor conditions alter barrier function;
• formulation dosing is inconsistent;
• sampling times do not adequately characterize the permeation profile;
• or the statistical design does not appropriately account for donor and replicate variability.

Research has shown that IVPT results can display considerable inter-study and inter-laboratory variability, highlighting the importance of standardized experimental design and careful interpretation. FDA’s draft guidance similarly emphasizes systematic IVPT method development before validation and pivotal comparative studies because inadequate development increases the risk of unsuitable validation or BE studies. A robust study therefore begins long before the first sample is collected.  

Factor 1: Clearly Define the Purpose of the IVPT Study

The first question should be: What is this IVPT study intended to demonstrate? The study may be designed to support:

• formulation screening;
• excipient evaluation;
• prototype optimization;
• understanding of topical pharmacokinetics;
• comparison of test and reference products;
• evaluation of formulation changes;
• regulatory development;
• or a topical bioequivalence strategy.

The intended purpose influences almost every later decision. For example, an exploratory formulation-screening experiment may not require the same donor number or statistical rigor as a pivotal comparative study intended to support a regulatory submission. The study objective should therefore be established before selecting:

• skin donors;
• replicate numbers;
• dosing conditions;
• sampling schedules;
• endpoints;
• or statistical methods.

FDA specifically notes that an IVPT method intended to support BE should be developed systematically so the resulting flux profiles can reliably compare the cutaneous pharmacokinetics of test and reference topical products.  

Factor 2: Select an Appropriate Skin Source

The biological membrane is one of the most important components of an IVPT study. For topical drug development, excised human skin is generally considered highly relevant because it represents the barrier through which the drug must permeate clinically. IVPT research commonly uses human skin mounted in Franz-type or flow-through diffusion cells. Important skin-related variables can include:

• donor source;
• anatomical site;
• donor age;
• donor sex;
• skin thickness;
• storage conditions;
• preparation method;
• dermatoming;
• and barrier integrity.

Human skin variability cannot be eliminated completely. The goal is to control and account for it scientifically. FDA’s topical IVPT framework specifically refers to barrier-competent human skin in diffusion-cell systems for product-specific comparative studies.  

Factor 3: Use Multiple Donors and an Appropriate Replicate Strategy

IVPT studies must account for biological variability. Skin sections from a single donor cannot fully represent the variability expected across a population. A stronger design uses multiple skin donors and replicate sections within each donor. This allows the experiment to distinguish: Product-related differences from Donor-related biological variability. FDA educational materials on characterization-based topical BE approaches have described pilot IVPT designs using skin from multiple donors, with several replicate sections per donor and treatment, to help characterize variability and estimate the sample size needed for pivotal studies. The exact number of donors and replicates should be justified for the specific study. A key principle is: More diffusion cells do not compensate for insufficient donor diversity. A study with many replicates from very few donors may provide excellent technical replication while inadequately representing biological variability.  

Factor 4: Confirm Skin Barrier Integrity

A permeation study is meaningful only if the skin retains an appropriately competent barrier. Damaged skin can permit artificially high drug permeation and distort product comparisons. Common approaches used to evaluate skin integrity include:

• transepidermal water loss (TEWL);
• electrical resistance;
• and permeability-based integrity tests.

FDA and OECD-related approaches have historically incorporated skin-integrity screening. However, recent research also shows that integrity tests should not be interpreted uncritically. A large retrospective analysis involving more than 17,000 skin sections found only limited relationships between commonly used integrity tests and drug permeation for many topical products. The practical implication is important: Skin-integrity testing is valuable, but it should be interpreted within the complete IVPT quality-control framework rather than treated as a perfect predictor of drug permeation.  

Factor 5: Select the Receptor Medium Carefully

The receptor phase must support collection and quantitation of the drug that permeates through the skin. A suitable receptor medium should provide adequate drug solubility while avoiding unnecessary alteration of the skin barrier. This balance can be difficult for poorly water-soluble APIs. Potential receptor-medium components may include:

• buffers;
• salts;
• proteins;
• cyclodextrins;
• co-solvents;
• or other scientifically justified additives.

However, additives should be evaluated carefully. For example, research comparing receptor solutions found that certain additives increased drug solubility without major effects on skin permeability, whereas a relatively high ethanol concentration significantly altered skin permeability and electrical resistance. Therefore: The receptor medium should support analytical recovery without becoming an unintended permeation enhancer. This is one of the most important scientific balances in IVPT method development.  

Factor 6: Define Dose Application and Exposure Conditions

Topical products are typically applied to the skin in relatively small amounts under finite-dose conditions. Dose application should be standardized because differences in applied amount or spreading can change permeation. Important considerations include:

• dose per unit area;
• application technique;
• spreading area;
• formulation loss during dosing;
• occluded versus unoccluded conditions;
• exposure duration;
• and dose removal procedures where applicable.

Dose conditions should reflect the study objective and relevant regulatory strategy. Some FDA product-specific recommendations for topical products use unoccluded finite-dose IVPT designs with multiple replicates per treatment. The dose should not simply be selected because it produces easily measurable receptor concentrations. It should also support a scientifically meaningful permeation experiment.  

Factor 7: Control Diffusion-Cell Conditions

IVPT commonly uses static Franz diffusion cells or flow-through diffusion systems. Key experimental variables include:

• diffusion area;
• receptor volume;
• temperature;
• stirring;
• cell assembly;
• skin orientation;
• receptor-medium contact;
• sampling-port configuration;
• and absence of bubbles beneath the skin.

Even small inconsistencies can affect measured permeation. For example, poor contact between the receptor medium and dermal surface may reduce effective transport. Air bubbles can effectively reduce available diffusion area. Temperature can alter both skin transport and formulation properties. The diffusion system must therefore be carefully standardized and appropriately qualified. IVPT protocols described in the literature emphasize controlled diffusion-cell conditions together with fit-for-purpose analytical procedures.  

Factor 8: Design the Sampling Schedule Around the Permeation Profile

IVPT is fundamentally a kinetic study. A single endpoint cannot fully describe how rapidly drug permeates through the skin. Serial receptor samples are therefore collected to generate a permeation-versus-time profile. Sampling times should allow characterization of:

• onset of permeation;
• increase in flux;
• maximum flux where relevant;
• duration of permeation;
• cumulative amount permeated;
• and potential late-stage changes.

FDA’s draft IVPT guidance describes flux profiles as analogous in some respects to pharmacokinetic profiles and discusses endpoints relating to the rate and extent of absorption. Product-specific FDA materials have described endpoints such as:

• maximum flux (Jmax);
• and total cumulative amount permeated (AMT).

The sampling schedule should therefore capture the shape of the permeation profile rather than focusing only on the final receptor concentration.  

Factor 9: Use a Fit-for-Purpose Bioanalytical Method

IVPT can generate complex sample types. Depending on study design, analysis may involve:

• receptor samples;
• epidermis;
• dermis;
• residual formulation;
• surface wash;
• or other relevant fractions.

Analytical sensitivity becomes particularly important when permeated drug concentrations are low. Suitable methods may include LC-MS/MS, HPLC, or other appropriately validated analytical techniques depending on the analyte and study objective. IVPT protocols in the scientific literature emphasize the need for fit-for-purpose bioanalytical methods capable of quantifying drugs in relevant IVPT sample matrices. Important analytical considerations include:

• sensitivity;
• selectivity;
• accuracy;
• precision;
• matrix effects;
• sample stability;
• extraction recovery;
• and calibration range.

The bioanalytical method should support the IVPT design not force the IVPT design to accommodate analytical limitations.  

Factor 10: Plan the Statistical Analysis Before the Study Begins

Statistical planning should be part of IVPT study design, not an afterthought. The study structure may contain multiple levels of variability: Between products Between donors Between skin sections from the same donor Between diffusion cells Analytical variability A statistically appropriate design should reflect this structure. For comparative studies, predefined endpoints and analysis methods should be selected before the pivotal experiment begins. Pilot studies can provide valuable estimates of variability and help determine how many donors and replicates may be required in a later comparative study. FDA specifically notes the value of pilot studies for evaluating permeation profiles, precision, reproducibility, selectivity, dose depletion, and sample-size considerations. Poor statistical planning can make a technically well-executed IVPT study difficult to interpret.  

The Role of Pilot IVPT Studies

A pilot study is one of the most valuable risk-reduction tools in IVPT development. The pilot can help answer questions such as:

• Does the API permeate at quantifiable levels?
• Is the sampling schedule appropriate?
• Is the receptor medium suitable?
• Is the skin preparation method reproducible?
• Is variability manageable?
• Does the method distinguish relevant product differences?
• How many donors may be required in the pivotal study?
• Are the planned analytical endpoints feasible?

FDA’s draft framework recommends systematic exploratory method-development studies and describes pilot studies as useful for establishing whether proposed conditions are appropriate before pivotal work. A pilot study should therefore be treated as method development, not merely as a miniature pivotal study.  

Why Donor Variability Matters So Much in IVPT

Donor variability is one of the defining characteristics of IVPT. Differences in:

• skin thickness;
• lipid composition;
• age;
• anatomical location;
• barrier characteristics;
• hydration;
• follicular density;
• and storage history

can influence permeation. Recent work examining variability across published human-skin IVPT datasets found substantial experimental heterogeneity, reinforcing the need to account for both biological and laboratory sources of variability. A well-designed study therefore does not try to eliminate donor variability. It incorporates it into the design.  

IVPT Study Design and Topical Formulation Properties

IVPT should be interpreted alongside knowledge of the formulation. Skin delivery can be influenced by:

• API thermodynamic activity;
• API solubility;
• excipient interactions;
• viscosity;
• rheology;
• evaporation;
• occlusion;
• microstructure;
• emulsion characteristics;
• and drug partitioning between formulation and skin.

Research comparing topical semisolid formulations has shown that differences in microstructure and rheological properties can translate into differences in skin permeation performance. More recent product-comparison research has likewise demonstrated that IVPT can distinguish differences in bioavailability between topical formulations containing the same therapeutic agent. This creates an important development framework: Formulation composition → Microstructure → Drug release → Skin interaction → Permeation profile IVPT sits toward the end of that mechanistic chain.  

IVPT and Q1/Q2/Q3 Characterization

For topical generic development, IVPT may be interpreted as part of a broader evidence package rather than as an isolated study. A useful conceptual sequence is: Q1 composition ↓ Q2 composition ↓ Q3 physicochemical and structural characterization ↓ IVRT ↓ IVPT ↓ Integrated bioequivalence assessment FDA finalized its guidance on Q3 characterization of topical drug products submitted in ANDAs in March 2026, reinforcing the importance of understanding physicochemical and structural properties that may be critical to topical product performance. The European Medicines Agency also has an adopted guideline on quality and equivalence of locally applied, locally acting cutaneous products that addresses in vitro performance and equivalence approaches. The precise evidence required remains product- and pathway-specific.  

IVPT vs IVRT: Why Study Design Is Different

IVRT and IVPT are complementary but fundamentally different studies.

IVRT

IVRT primarily evaluates drug release from the formulation. It commonly uses a synthetic membrane designed not to provide a biologically relevant skin barrier.

IVPT

IVPT evaluates drug permeation through a biological skin barrier. This introduces:

• donor variability;
• skin integrity;
• tissue preparation;
• biological transport;
• formulation–skin interactions;
• and more complex statistical considerations.

This is why an IVRT method cannot simply be converted into an IVPT method by replacing the synthetic membrane with skin. The entire experimental strategy must be reconsidered.  

Common IVPT Study Design Challenges

Excessive Donor Variability

This may require improved donor balancing, replicate design, or statistical planning rather than arbitrary exclusion of data.

Low Drug Permeation

Potential contributors include low API thermodynamic activity, skin barrier properties, receptor-medium conditions, or inadequate analytical sensitivity.

High Cell-to-Cell Variability

Check dosing consistency, skin preparation, cell assembly, bubbles, temperature, and sampling technique.

Compromised Skin Integrity

Review tissue preparation, handling, storage, dermatoming, and integrity-testing procedures.

Receptor-Medium Problems

Ensure that the medium provides suitable analyte solubility without materially disrupting skin-barrier function.

Poor Discriminatory Ability

Revisit study conditions, dose, sampling schedule, product controls, and formulation differences.

Inadequate Statistical Power

Use pilot data to understand donor and replicate variability before pivotal study design.  

Best Practices for IVPT Study Design

Start With the Regulatory and Scientific Objective

Define what the study needs to demonstrate before selecting the experimental setup.

Conduct Systematic Method Development

Do not move directly into validation or pivotal comparison without understanding critical IVPT variables.

Use Relevant Human Skin

Where appropriate for the study objective, use barrier-competent human skin and document donor and tissue characteristics.

Incorporate Multiple Donors

Design the study to account for biological variation.

Standardize Dosing

Control the applied dose per unit area and application technique.

Justify the Receptor Medium

Balance analyte solubility with preservation of skin-barrier function.

Use a Meaningful Sampling Schedule

Capture the complete permeation profile rather than relying only on a terminal time point.

Use Fit-for-Purpose Bioanalysis

Ensure the method can quantify the expected concentration range reliably.

Plan Statistics Prospectively

Define endpoints and analytical methods before pivotal testing.

Integrate IVPT With Product Characterization

Interpret permeation data alongside Q1/Q2/Q3 characterization, IVRT, rheology, and other relevant formulation information. At topiox research, this integrated strategy can help connect observed IVPT differences to the underlying formulation and product-performance mechanisms.  

IVPT Study Design at topiox research

A robust IVPT program combines several scientific disciplines:

• formulation development;
• ex vivo skin handling;
• diffusion-cell science;
• receptor-medium development;
• bioanalytical method development;
• donor and replicate design;
• statistical analysis;
• Q3 characterization;
• and topical regulatory strategy.

At topiox research, IVPT study design can be integrated with broader topical drug-development programs so that permeation results are evaluated in the context of formulation composition, microstructure, drug release, and intended regulatory use. This approach helps answer not only: “Are two IVPT profiles different?” but also: “What scientific factors may explain the difference, and what does that mean for the development strategy?”

Conclusion

Successful IVPT study design depends on controlling experimental variability without removing the biological variability that makes human skin a meaningful model. The ten factors that deserve particular attention are:

1. Define the IVPT study objective.
2. Select an appropriate skin source.
3. Use multiple donors and a justified replicate strategy.
4. Confirm skin-barrier integrity.
5. Select and justify the receptor medium.
6. Standardize dose and exposure conditions.
7. Control diffusion-cell operating conditions.
8. Design sampling around the permeation profile.
9. Use fit-for-purpose bioanalytical methods.
10. Plan the statistical analysis prospectively.

The central principle is: An IVPT study should be sensitive enough to detect meaningful product differences, reproducible enough to support reliable interpretation, and biologically relevant enough to characterize cutaneous drug permeation. Research consistently shows that IVPT is capable of characterizing topical product performance, while also demonstrating that donor variability, receptor-medium composition, formulation properties, and study execution can materially influence the results. At topiox research, IVPT study design can be integrated with formulation science, Q3 characterization, IVRT, bioanalysis, and topical regulatory strategy to generate data that are not only statistically interpretable but scientifically meaningful.